$BHVN earnings report

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results. AlphAI read Biohaven's Third Quarter 2026 filing as mixed. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readBHVN · Third Quarter 2026 · ended September 30, 2026

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

→Mixed quarter

Third-quarter operating expenses and net loss declined year over year, while Biohaven secured significant partnership consideration and advanced several pipeline programs. Offsetting these developments, the company remains pre-revenue with a $129.3 million quarterly net loss, and opakalim new enrollment is subject to an FDA partial clinical hold pending additional nonclinical data.

EPS · non-GAAP
$0.73

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, three months ended September 30GAAP$101.9M–decrease of $39.3 million
General and administrative expenses, three months ended September 30GAAP$24.6M–decrease of $3.6 million
Total operating expenses, three months ended September 30GAAP$126.4M––
Loss from operations, three months ended September 30GAAP−$126.4M––
Other expense, net, three months ended September 30GAAP$2.9M–decrease in expense of $0.9 million
Loss before benefit provision for income taxes, three months ended September 30GAAP−$129.3M––
Benefit provision for income taxes, three months ended September 30GAAP−$64K––
Net loss, three months ended September 30GAAP$129.3M––
Net loss per share, basic and diluted, three months ended September 30GAAP$0.86 per share––
Weighted average common shares outstanding, basic and diluted, three months ended September 30GAAP151,040,349––
Non-GAAP adjusted net loss, three months ended September 30non-GAAP$110.7M––
Non-GAAP adjusted net loss per share, basic and diluted, three months ended September 30non-GAAP$0.73 per share––
Non-cash share-based compensation expense, three months ended September 30GAAP$12.1M–decrease of $1.9 million
Non-cash share-based compensation expense in general and administrative expenses, three months ended September 30GAAP$6.6M–decrease of $1.0 million
Research and development expenses, nine months ended September 30GAAP$306.5M––
General and administrative expenses, nine months ended September 30GAAP$75.26M––
Total operating expenses, nine months ended September 30GAAP$381.7M––
Loss from operations, nine months ended September 30GAAP−$381.7M––
Other expense income, net, nine months ended September 30GAAP−$14.78M––
Loss before benefit provision for income taxes, nine months ended September 30GAAP−$396.5M––
Benefit provision for income taxes, nine months ended September 30GAAP$599K––
Net loss, nine months ended September 30GAAP−$397.1M––
Net loss per share, basic and diluted, nine months ended September 30GAAP$ (2.65)––
Weighted average common shares outstanding, basic and diluted, nine months ended September 30GAAP149,776,602––
Non-GAAP adjusted net loss, nine months ended September 30non-GAAP−$331.0M––
Non-GAAP adjusted net loss per share, basic and diluted, nine months ended September 30non-GAAP$ (2.21)––
Cash and cash equivalents, September 30, 2026GAAP$95.75M––
Marketable securities, September 30, 2026GAAP$65.37M––
Total assets, September 30, 2026GAAP$263.7M––
Notes payable, September 30, 2026GAAP$264.3M––
Total liabilities, September 30, 2026GAAP$361.9M––
Total shareholders' deficit equity, September 30, 2026GAAP−$98.25M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Expected Upcoming Milestones outlook

  • NoteVyglxia (troriluzole) in SCA: FDA advisory committee meeting (date to be announced); user fee goal date in 1Q 2027.
  • NoteSelective Kv7 Ion Channel Activator (Opakalim): Topline results for Phase 2/3 study expected in 2H 2026.
  • NoteMyostatin-Activin Pathway Inhibitor (Taldefgrobep alfa): topline data expected in 2H 2027.
  • NoteBHV-1300: Continue enrollment of patients in ongoing Phase 3 study in Graves' disease.
  • NoteBHV-1400: Pivotal study initiation in IgAN targeted for 2H 2026.
  • NoteBiohaven will receive an additional $350.0 million from SKBP upon the closing of the SKBP Agreement.
  • NoteBiohaven will receive a $20 million milestone payment upon achievement of a milestone anticipated within a year of signing.

What drove it

  • Research and development expenses decreased primarily because of decreases in direct program spend and preclinical spend following the strategic reprioritization of programs implemented in the fourth quarter of 2025.
  • Ono licensing agreement provides up to $100 million in near-term payments, consisting of an $80 million upfront payment received to date and a $20 million milestone payment anticipated within a year, plus royalties of approximately 20 percent on net sales in the licensed territory.
  • The SK Biopharmaceuticals agreement provides $400 million in cash consideration, consisting of $350 million payable at closing and $50 million payable one year after closing, plus eligibility for up to $150 million in development and regulatory milestone payments.
  • The FDA accepted the Vyglxia new drug application resubmission for review and assigned a user fee goal date in the first quarter of 2027.
  • BHV-1300 enrollment is ongoing in its Phase 3 Graves' disease study, and BHV-1400 pivotal-study initiation in IgAN is targeted for 2H 2026.

Concerns

  • The FDA issued a partial clinical hold letter on September 4, 2026, pausing new patient enrollment for opakalim until additional clarifying nonclinical studies are completed.
  • The significance of the nonclinical metabolite findings to humans is uncertain.
  • Biohaven reported a GAAP net loss of $129.3 million for the three months ended September 30, 2026.
  • Notes payable were $ 264,294 (Amounts in thousands), and total shareholders' deficit equity was $ (98,247) (Amounts in thousands) as of September 30, 2026.
  • The SK Biopharmaceuticals transaction remains subject to remaining closing conditions.

What to watch

  • Opakalim RISE 3 topline data, which remains on track for the second half of 2026.
  • Completion of additional opakalim nonclinical studies and the status of the partial clinical hold on new enrollment.
  • Closing of the SK Biopharmaceuticals agreement and receipt of the $350 million payment payable at closing.
  • The FDA advisory committee meeting date and the first-quarter 2027 user fee goal date for Vyglxia in SCA.
  • BHV-1400 pivotal-study initiation in IgAN targeted for 2H 2026.
  • Taldefgrobep alfa Phase 2 monotherapy and combination-therapy topline data expected in 2H 2027.

Balance sheet and cash flow

  • Cash, cash equivalents, marketable securities and restricted cash as of September 30, 2026, totaled approximately $164.0 million.
  • On October 20, 2026, Biohaven received $80.0 million from Ono Pharmaceuticals.
  • Notes payable were $ 264,294 (Amounts in thousands) as of September 30, 2026.
  • Operating cash flow and free cash flow were not reported.

Analysis

Biohaven remained a clinical-stage company without reported revenue and recorded a GAAP net loss of $129.3 million, or $0.86 per share, for the three months ended September 30, 2026. The loss narrowed from $173.4 million, or $1.64 per share, in the prior-year period. Non-GAAP adjusted net loss was $110.7 million, or $0.73 per share, compared with $155.9 million, or $1.47 per share.

The improvement was driven by lower operating spending. R&D expense was $101.9 million, down $39.3 million, principally from reduced direct program and preclinical spend after the program reprioritization implemented in the fourth quarter of 2025. G&A expense was $24.6 million, down $3.6 million, primarily due to lower employee costs including share-based compensation. Other expense, net was $2.9 million, compared with $3.8 million.

The principal strategic development was the monetization of two pipeline platforms. Biohaven received $80.0 million from Ono Pharmaceuticals on October 20, 2026 and may receive up to $100 million in near-term payments under the regional MoDE portfolio license. The SK Biopharmaceuticals agreement provides for $400 million in cash consideration, including $350 million at closing, while SKBP will assume Kv7 program costs going forward. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $164.0 million as of September 30, 2026, before the reported Ono receipt and prospective SKBP closing payment.

Pipeline execution remains central to the period. The FDA accepted the Vyglxia resubmission in SCA, with a user fee goal date in the first quarter of 2027, while BHV-1300 is enrolling in Phase 3 and BHV-1400 pivotal-study initiation is targeted for 2H 2026. The key near-term risk is the partial clinical hold on new opakalim enrollment following metabolite findings in rodent testing. Biohaven stated that more than 600 randomized patients can continue dosing, RISE 3 is fully enrolled, and its topline data remains on track for the second half of 2026.

Management, verbatim

This quarter marked important progress in executing our strategy of building differentiated platforms and partnering them to create both near-term and long-term value.

Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven

Beyond these partnerships, we continue to advance a diverse and innovative pipeline.

Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven

Not in the filing

stated, not guessed
  • Total revenue and revenue growth were not reported.
  • Segment revenue and segment profitability were not reported.
  • Gross profit, gross margin, operating income, and operating margin were not reported.
  • Operating cash flow, capital expenditures, free cash flow, dividends, and share repurchases were not reported.
  • Financial revenue, gross-margin, operating-expense, or tax-rate guidance was not reported.
  • Prior-quarter comparisons were not reported.
  • The previous outlook covered the second half of 2026 and contained only qualitative milestones with no numeric figures, so there is nothing to compare with this third quarter report.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readBHVN · Second Quarter 2026 · ended June 30, 2026

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results

→Mixed quarter

Second-quarter operating expenses and net loss declined materially from the prior-year period following program reprioritization and lower direct and preclinical spend, while the company advanced several clinical programs. The filing reports no revenue, continued net losses, $259,480 (Amounts in thousands) of notes payable, and key value-driving clinical readouts and pivotal-study initiations remain ahead in 2H 2026.

EPS · non-GAAP
$0.78

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expensesGAAP$100.8M–decrease of $83.6 million
General and administrative expensesGAAP$24.1M–decrease of $3.2 million
Total operating expensesGAAP$124.9M––
Loss from operationsGAAP−$124.9M––
Other (expense) income, netGAAPother expense, net of $12.0 million–decrease of $25.8 million
Loss before provision for income taxesGAAP−$136.9M––
Provision for income taxesGAAP391K––
Net lossGAAP$137.3M––
Net loss per shareGAAP$0.91 per share––
Weighted average common shares outstanding, basic and dilutedother150,636,620––
Non-cash share-based compensation expenseGAAP$12M–decrease of $1.1 million
Non-cash share-based compensation expense in general and administrative expensesGAAP$7.2M–decrease of $0.5 million
Non-GAAP adjusted net lossnon-GAAP$118.1M––
Non-GAAP adjusted net loss per sharenon-GAAP$0.78 per share––
Six-month research and development expensesGAAP$204.6M––
Six-month general and administrative expensesGAAP50.69M––
Six-month total operating expensesGAAP255.3M––
Six-month loss from operationsGAAP−255.3M––
Six-month other (expense) income, netGAAP−11.85M––
Six-month loss before provision for income taxesGAAP−267.2M––
Six-month provision for income taxesGAAP663K––
Six-month net lossGAAP−$267.8M––
Six-month net loss per share, basic and dilutedGAAP$ (1.80)––
Six-month weighted average common shares outstanding, basic and dilutedother149,134,255––
Six-month non-GAAP adjusted net lossnon-GAAP−$220.4M––
Six-month non-GAAP adjusted net loss per share, basic and dilutednon-GAAP$ (1.48)––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2H 2026 outlook

  • NoteTopline results from the Phase 2/3 RISE3 trial in focal epilepsy are expected during 2H 2026.
  • NoteTopline data expected during 2H 2026 for the Phase 2 study of taldefgrobep alfa in obesity.
  • NoteBHV-1400: Pivotal study initiation in IgAN study targeted for 2H 2026.
  • NoteNew data on BHV-1530 will be presented at the ESMO Congress 2026 in October 2026.
  • NoteContinue enrolling patients in the ongoing Phase 3 study in Graves' disease following June 2026 study initiation.

What drove it

  • R&D expenses decreased primarily because of decreases in direct program spend and preclinical spend in 2026 compared with the same period in the prior year.
  • The decrease in direct program spend was largely due to strategic reprioritization of programs implemented in the fourth quarter of 2025 and one-time developmental milestones of $15.0 million for BHV-8000 and $10.0 million for BHV-1530 recorded during the three months ended June 30, 2025.
  • G&A expenses declined primarily because of decreased legal costs and employee costs, including non-cash share based compensation expense.
  • Other (expense) income, net declined primarily due to increased non-cash losses related to changes in fair value of notes payable liability under the NPA and gains recorded in the prior-year period for non-cash changes in fair value of forward contracts and derivative liabilities.
  • The company initiated a pivotal Phase 3 study of BHV-1300 in Graves' disease and plans to initiate a pivotal Phase 3 study of BHV-1400 in IgAN in 2H 2026.

Concerns

  • The company reported a GAAP net loss of $137.3 million for the three months ended June 30, 2026.
  • The filing reports no revenue or commercial segment revenue.
  • Notes payable were 259,480 (Amounts in thousands) as of June 30, 2026.
  • Other expense, net was $12.0 million in the second quarter of 2026, versus other income, net of $13.8 million in the prior-year period.
  • The pivotal readout for opakalim and topline obesity data are expected during 2H 2026, while BHV-1400 pivotal-study initiation is targeted for 2H 2026.

What to watch

  • Topline results for the first Phase 2/3 opakalim study in focal epilepsy expected in 2H 2026.
  • Topline data from the Phase 2 obesity study of taldefgrobep alfa expected during 2H 2026.
  • Progress of enrollment in the randomized, double-blind, placebo-controlled Phase 3 BHV-1300 study in approximately 300 adults with Graves' hyperthyroidism.
  • Initiation of the BHV-1400 pivotal study in IgAN targeted for 2H 2026.
  • New BHV-1530 Phase 1 data scheduled for presentation at the ESMO Congress 2026 in October 2026.

Balance sheet and cash flow

  • Cash, cash equivalents, marketable securities and restricted cash as of June 30, 2026, totaled approximately $270.5 million.
  • Cash and cash equivalents were $ 238,033 (Amounts in thousands) as of June 30, 2026, compared to $ 229,957 (Amounts in thousands) as of December 31, 2025.
  • Marketable securities were 29,833 (Amounts in thousands) as of June 30, 2026, compared to 89,180 (Amounts in thousands) as of December 31, 2025.
  • Notes payable were 259,480 (Amounts in thousands) as of June 30, 2026, compared to 238,900 (Amounts in thousands) as of December 31, 2025.
  • Total assets were $ 370,739 (Amounts in thousands) as of June 30, 2026, compared to $ 451,447 (Amounts in thousands) as of December 31, 2025.
  • Total liabilities were 358,517 (Amounts in thousands) as of June 30, 2026, compared to 399,375 (Amounts in thousands) as of December 31, 2025.
  • Total shareholders' equity was 12,222 (Amounts in thousands) as of June 30, 2026, compared to 52,072 (Amounts in thousands) as of December 31, 2025.

Analysis

Biohaven remained a clinical-stage company in the second quarter, with the filing reporting no revenue and a GAAP net loss of $137.3 million, or $0.91 per share. The loss improved from $198.1 million, or $1.94 per share, in the same period of 2025. Non-GAAP adjusted net loss was $118.1 million, or $0.78 per share, compared with $166.4 million, or $1.63 per share. The non-GAAP measure excludes non-cash share-based compensation and changes in the fair value of derivative liabilities.

The main financial change was lower spending. R&D expense fell to $100.8 million from $184.4 million, and G&A expense declined to $24.1 million from $27.3 million. Management attributed the R&D reduction to lower direct program and preclinical spending, its fourth-quarter 2025 strategic program reprioritization, and prior-year one-time developmental milestones for BHV-8000 and BHV-1530. These reductions brought total operating expenses to $124,899 (Amounts in thousands), compared with $211,701 (Amounts in thousands) a year earlier.

Clinical execution is centered on the extracellular-degrader and neuroscience pipelines. Biohaven initiated a pivotal Phase 3 study of BHV-1300 in Graves' disease after Phase 1b data in which weekly 1000 mg subcutaneous administration achieved mean reductions of pathogenic TSHR-IgG1 autoantibodies of greater than 80% by week 12. It also reported that BHV-1400 achieved mean reductions of pathogenic Gd-IgA1 of greater than 60% within 48 hours and approximately 70% within the first month of dosing. The next major anticipated clinical events are opakalim focal-epilepsy results and taldefgrobep alfa obesity data in 2H 2026, as well as BHV-1400 pivotal-study initiation targeted for 2H 2026.

Liquidity and liabilities warrant attention alongside the clinical calendar. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $270.5 million as of June 30, 2026, while notes payable were 259,480 (Amounts in thousands). Other expense, net was $12.0 million, compared with other income, net of $13.8 million in the prior-year period, principally reflecting non-cash fair-value losses on the notes payable liability and prior-year derivative-related gains. The filing provides no financial revenue, margin, operating-expense, or tax-rate guidance, so the disclosed outlook is limited to development milestones.

Management, verbatim

What excites me most about Biohaven today is that we're no longer talking about scientific promise—we're watching new therapeutic approaches begin to work in patients.

Vlad Coric, M.D., Chairman and Chief Executive Officer

If these data continue to translate into larger studies, extracellular protein degradation has the potential to reshape how autoimmune diseases are treated.

Vlad Coric, M.D., Chairman and Chief Executive Officer

As we approach our pivotal readout later this year, we believe we have the opportunity to introduce an important new treatment option for patients who deserve both seizure control and the ability to fully participate in their everyday lives.

Vlad Coric, M.D., Chairman and Chief Executive Officer

Not in the filing

stated, not guessed
  • Revenue for the three months ended June 30, 2026 and prior-year comparison were not reported.
  • Revenue segments and segment revenue comparisons were not reported.
  • Gross profit and gross margin were not reported.
  • Operating cash flow and free cash flow were not reported.
  • Share repurchases, dividends, and other capital-return activity were not reported.
  • Financial guidance for revenue, gross margin, operating expenses, and tax rate was not reported.
  • A prior outlook section was not provided, so comparison of actual results with prior guidance is unavailable.
  • Quarter-over-quarter comparisons for reported financial metrics were not reported.
  • Tax rate was not reported.
  • Restricted cash as a separate balance-sheet line item was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about BHVN earnings dates

When is Biohaven's next earnings date?
AlphAI has no date for BHVN yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.